{'fraction_non_alphanumeric': 0.03619441571871768, 'fraction_numerical': 0.02688728024819028, 'mean_word_length': 4.9753086419753085, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Changes in Solvent Composition in Tandem Mass Spectrometry Multiplex Assay for Lysosomal Storage Disorders Do Not Affect Assay Results

served in our laboratory. In summary, the presence of 5 g/dL (50 g/L) of M-protein results in BCP albumin determinations that are approximately 30% lower than those obtained using capillary SPEP. According to the International Myeloma Staging System, samples with albumin values of 3.5 g/dL (35 g/L) can potentially be classified as stage I in the absence of increased serum 2-microglobulin. Here, 521 samples had albumin concentrations 3.5 g/dL (35 g/L) by BCP assay, whereas only 374 samples exhibited albumin concentrations 3.5 g/dL (35 g/L) by capillary electrophoresis. Because the Multiple Myeloma International Staging System does not specify a preferred method for albumin determination, clinicians should be aware of these differences in methods when interpreting albumin concentrations in myeloma patient samples (1, 5 ).